Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

2.

Burger

JA

,

Tedeschi

A

,

Barr

PM

, et al.

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

.

N Engl J Med

.

2015

;

373

(

25

):

2425

-

2437

.

3.

Woyach

JA

,

Ruppert

AS

,

Heerema

NA

, et al.

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL

.

N Engl J Med

.

2018

;

379

(

26

):

2517

-

2528

.

4.

Shanafelt

TD

,

Wang

XV

,

Kay

NE

, et al.

Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia

.

N Engl J Med

.

2019

;

381

(

5

):

432

-

443

.

5.

Byrd

JC

,

Hillmen

P

,

Ghia

P

, et al.

Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial

.

J Clin Oncol

.

2021

;

39

(

31

):

3441

-

3452

.

6.

Brown

JR

,

Eichhorst

B

,

Hillmen

P

, et al.

Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia

.

N Engl J Med

.

2023

;

388

(

4

):

319

-

332

.

7.

Tam

C

,

Thompson

PA

.

BTK inhibitors in CLL: second-generation drugs and beyond

.

Blood Adv

.

2024

;

8

(

9

):

2300

-

2309

.

8.

Woyach

JA

,

Furman

RR

,

Liu

T-M

, et al.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

.

N Engl J Med

.

2014

;

370

(

24

):

2286

-

2294

.

9.

Maddocks

KJ

,

Ruppert

AS

,

Lozanski

G

, et al.

Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia

.

JAMA Oncol

.

2015

;

1

(

1

):

80

-

87

.

10.

Kanagal-Shamanna

R

,

Jain

P

,

Patel

KP

, et al.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation

.

Cancer

.

2019

;

125

(

4

):

559

-

574

.

11.

Furman

RR

,

Cheng

S

,

Lu

P

, et al.

Ibrutinib resistance in chronic lymphocytic leukemia

.

N Engl J Med

.

2014

;

370

(

24

):

2352

-

2354

.

12.

Cheng

S

,

Guo

A

,

Lu

P

,

Ma

J

,

Coleman

M

,

Wang

YL

.

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors

.

Leukemia

.

2015

;

29

(

4

):

895

-

900

.

13.

Bonfiglio

S

,

Sutton

LA

,

Ljungstrom

V

, et al.

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

.

Blood Adv

.

2023

;

7

(

12

):

2794

-

2806

.

14.

Woyach

JA

,

Ghia

P

,

Byrd

JC

, et al.

B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy

.

Clin Cancer Res

.

2023

;

29

(

16

):

3065

-

3073

.

15.

Woyach

JA

,

Jones

D

,

Jurczak

W

, et al.

Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

.

Blood

.

2024

;

144

(

10

):

1061

-

1068

.

16.

Blombery

P

,

Thompson

ER

,

Lew

TE

, et al.

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

.

Blood Adv

.

2022

;

6

(

20

):

5589

-

5592

.

17.

Rogers

KA

,

Thompson

PA

,

Allan

JN

, et al.

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

.

Haematologica

.

2021

;

106

(

9

):

2364

-

2373

.

18.

Li

W

,

Sano

R

,

Apatira

M

, et al.

Bruton's tyrosine kinase inhibitors with distinct binding modes reveal differential functional impact on B-cell receptor signaling

.

Mol Cancer Ther

.

2024

;

23

(

1

):

35

-

46

.

19.

Thompson

PA

,

Tam

CS

.

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

.

Blood

.

2023

;

141

(

26

):

3137

-

3142

.

20.

Mato

AR

,

Shah

NN

,

Jurczak

W

, et al.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

.

Lancet

.

2021

;

397

(

10277

):

892

-

901

.

21.

Mato

AR

,

Woyach

JA

,

Brown

JR

, et al.

Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia

.

N Engl J Med

.

2023

;

389

(

1

):

33

-

44

.

22.

Woyach

JA

,

Stephens

DM

,

Flinn

IW

, et al.

First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma

.

Cancer Discov

.

2024

;

14

(

1

):

66

-

75

.

23.

Wang

E

,

Mi

X

,

Thompson

MC

, et al.

Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors

.

N Engl J Med

.

2022

;

386

(

8

):

735

-

743

.

24.

Brown

J

,

Desikan

S

,

Nguyen

B

, et al.

Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

326

.

25.

Kadri

S

,

Lee

J

,

Fitzpatrick

C

, et al.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

.

Blood Adv

.

2017

;

1

(

12

):

715

-

727

.

26.

Hamasy

A

,

Wang

Q

,

Blomberg

KE

, et al.

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant

.

Leukemia

.

2017

;

31

(

1

):

177

-

185

.

27.

Montoya

S

,

Bourcier

J

,

Noviski

M

, et al.

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

.

Science

.

2024

;

383

(

6682

):

eadi5798

.

28.

Handunnetti

S

,

Tang

C

,

Nguyen

T

, et al.

BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

170

.

29.

Song

Y

,

Sun

M

,

Qi

J

, et al.

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies

.

Br J Haematol

.

2022

;

198

(

1

):

62

-

72

.

30.

Jackson

RA

,

Britton

RG

,

Jayne

S

, et al.

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib

.

Blood Adv

.

2023

;

7

(

14

):

3378

-

3381

.

31.

Qi

J

,

Endres

S

,

Yosifov

DY

, et al.

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors

.

Blood Adv

.

2023

;

7

(

19

):

5698

-

5702

.

32.

Dhami

K

,

Chakraborty

A

,

Gururaja

TL

, et al.

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

.

Sci Signal

.

2022

;

15

(

736

):

eabg5216

.

33.

Yang

G

,

Buhrlage

SJ

,

Tan

L

, et al.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

.

Blood

.

2016

;

127

(

25

):

3237

-

3252

.

34.

Woyach

J

,

Huang

Y

,

Rogers

K

, et al.

Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

504

.

35.

Estupinan

HY

,

Wang

Q

,

Berglof

A

, et al.

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

.

Leukemia

.

2021

;

35

(

5

):

1317

-

1329

.

36.

Brown

J

,

Li

J

,

Eichhorst

B

, et al.

Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1890

.

37.

Ahn

IE

,

Brander

DM

,

Ren

Y

, et al.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

.

Blood Adv

.

2024

;

8

(

4

):

832

-

841

.

38.

Naeem

A

,

Utro

F

,

Wang

Q

, et al.

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

.

Blood Adv

.

2023

;

7

(

9

):

1929

-

1943

.

39.

Casan

JML

,

Seymour

JF

.

Degraders upgraded: the rise of PROTACs in hematological malignancies

.

Blood

.

2024

;

143

(

13

):

1218

-

1230

.

40.

Gruber

M

,

Bozic

I

,

Leshchiner

I

, et al.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia

.

Nature

.

2019

;

570

(

7762

):

474

-

479

.